Aktuellt
SENASTE
The guaranteed right issue will secure growth capital supporting the US launch and to advance the European commercialisation based on distribution partners. Shareholders in Biovica have preferential rights to subscribe for six new class B shares per ten (A or B shares), i.e. a subscription ratio of six to ten share priced at SEK 8.65. This will trigger a Review of our earlier base case.
LÄS MER
